CTSO - CIK 0001175151
Cytosorbents Corp (CTSO) reported net income of -$8.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$8.20M | +60.4% |
| FY 2024 | -$20.72M | +29.2% |
| FY 2023 | -$29.25M | +10.9% |
| FY 2022 | -$32.81M | -33.6% |
| FY 2021 | -$24.56M | -213.4% |
| FY 2020 | -$7.84M | +59.3% |
| FY 2019 | -$19.27M | -11.9% |
| FY 2018 | -$17.21M | -103.4% |
| FY 2017 |
Cytosorbents Corp (CTSO) reported net income of -$8.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Cytosorbents Corp's net income declined from -$5.48M to -$8.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$8.46M |
| +28.1% |
| FY 2016 | -$11.76M | -24.1% |
| FY 2015 | -$9.48M | -1.7% |
| FY 2014 | -$9.32M | -99.3% |
| FY 2013 | -$4.68M | -27.7% |
| FY 2012 | -$3.66M | +33.2% |
| FY 2011 | -$5.48M | - |